Skip to main content

Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial

In brief

Intravenous iron raises peak oxygen uptake by 1.1 mL/kg/min in HFpEF

In a 65-person randomized trial, one intravenous dose of ferric derisomaltose improved peak oxygen uptake by 1.1 mL/kg/min more than placebo at 12 weeks. Walking distance and heart failure class also improved, but reported health status did not differ between groups. The short-term gains in exercise measures need confirmation in larger, longer trials.

Journal
Circulation (Q1)
Published
8 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Gregory D Lewis, Nora K Horick, Fabely Moreno, Kenneth Lim, Diane Cocca-Spofford, Takenori Ikoma, et al.
PMID
42999950
DOI
10.1161/CIRCULATIONAHA.126.084009

Why clinicians should know about it

Abstract

BACKGROUND: Iron deficiency is present in >50% of patients with heart failure with preserved ejection fraction and is associated with reduced exercise capacity and survival. Whether iron repletion improves exercise capacity as objectively measured by peak oxygen uptake ([Formula: see text]) is unknown. The IRONMET-HFpEF trial (Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in HFpEF) sought to determine whether ferric derisomaltose (FDI) compared with placebo improves peak [Formula: see text] in heart failure with preserved ejection fraction with iron deficiency. METHODS: This was a double-blind, placebo-controlled randomized clinical trial of patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin <100 ng/mL or <300 ng/mL with transferrin saturation <20%. Participants were enrolled between December 2021 and April 2026. Single-dose ferric derisomaltose (1000 mg; n=44) or placebo (n=21) was administered once intravenously. The primary end point was the change in peak [Formula: see text] from baseline to 12 weeks with an analysis of covariance model including terms for treatment group, baseline peak [Formula: see text], and sex. Secondary end points included changes in [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class, health status assessed by the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score, and iron biomarkers at 12 weeks. RESULTS: Among 65 randomized participants (median age, 68 years [interquartile range, 58-76 years], 72% women, transferrin saturation 16.0±7.4%, ferritin 57.8±48.9 ng/mL), 64 (98.5%) completed the study. The median baseline peak [Formula: see text] was 12.7 mL·kg-1·min-1 (interquartile range, 10.6-15.8 mL·kg-1·min-1) in the FDI group and 12.2 mL·kg-1·min-1 (11.6-14.6 mL·kg-1·min-1) in the placebo group. At 12 weeks, peak [Formula: see text] improved by 1.2 mL·kg-1·min-1 (95% CI, 0.6-1.7) in the FDI group and was unchanged (0.1 mL·kg-1·min-1 [95% CI, -0.7 to 0.9]) in the placebo group (least-squares mean difference, 1.1 mL·kg-1·min-1 [95% CI, 0.2-1.9]; P=0.02). [Formula: see text] at the anaerobic threshold, 6-minute walk test distance, and New York Heart Association class also improved in the FDI compared with the placebo group (all P<0.05), whereas the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score did not differ significantly between groups (FDI group, +4.4 [95% CI, -2.4 to 11.2]; P=0.20). FDI increased transferrin saturation (9.4% [95% CI, 4.9%-13.9%]) and ferritin (183 ng/mL [95% CI, 128-238]) compared with the placebo group (PLSMD<0.001 for both). There were no serious adverse events related to FDI administration. CONCLUSIONS: In the largest trial to date of iron repletion in heart failure with preserved ejection fraction with iron deficiency, FDI improved multiple measures of exercise capacity. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04945707.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.